Bullfrog AI Holdings shares surge 76.67% intraday after partnering with top-five global pharmaceutical firm to identify MDD drug targets using bfLEAP platform.

Bullfrog AI Holdings surged 76.67% intraday, following the announcement of a commercial agreement with one of the world’s top five pharmaceutical companies. The deal utilizes Bullfrog’s proprietary bfLEAP platform to identify and prioritize new drug targets for major depressive disorder (MDD), accelerating the client’s drug discovery and clinical development plans. The agreement grants the client exclusive rights to candidate targets and secures access to the MDD market, which exceeded $8 billion in 2025 and is projected to surpass $11 billion by 2032.